PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression

Дата публикации: 01-07-2026 00:00:00

This meta-analysis compares survival with programmed cell death 1 protein or programmed cell death 1 ligand 1 (PD-[L]1) inhibitor monotherapy vs chemoimmunotherapy in treatment-naive patients with advanced NSCLC and high PD-L1 expression.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer	0	10	28-07-2026
2	Pathologic Response After Neoadjuvant Chemoimmunotherapy in Head and Neck Squamous Cell Carcinoma	0	4.44	13-08-2026
3	Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer	0	14.28	01-01-2025
4	PFS in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review	0	8.34	16-07-2026
5	Checkpoint Inhibitors Plus Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors	0	4.57	01-09-2023
6	Rates of Systemic Treatment for Metastatic Non–Small Cell Lung Cancer Among Older Adults	0	5.92	01-07-2026
7	Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions	0	5	23-06-2026
8	Lung transplant dramatically improves survival for patients with terminal lung cancer, study finds	7	8	08-07-2026
9	Pathological response and exploratory assessment of pretreatment PD-L1 combined positive score after four cycles of neoadjuvant pembrolizumab plus chemotherapy in locally advanced head and neck squamous cell carcinoma: a retrospective cohort study	0	13.96	07-08-2026
10	Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC	0	5	30-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 15.58. Источник: archderm.jamanetwork.com.